Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Kelly et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69dcc30ed4d0de07d11339bd — DOI: https://doi.org/10.1200/jco.2015.61.8918

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non-small cell lung cancer (NSCLC) with activating mutation of epidermal growth factor receptor (EGFR): Thoracic Oncology Research Group (TORG) 0911.· 2014 · 2 citations
2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial· 2012 · 5,518 citations
3. Reduced-dose versus full-dose erlotinib for advanced EGFR-mutant non-small cell lung carcinoma (NSCLC): A retrospective analysis.· 2015 · 6 citations
4. Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial· 1975 · 2,360 citations
5. Revisions in the International System for Staging Lung Cancer· 1997 · 4,602 citations